Skip to main content
. Author manuscript; available in PMC: 2020 Mar 30.
Published in final edited form as: Biomed Pharmacother. 2019 Aug 7;118:109323. doi: 10.1016/j.biopha.2019.109323

Fig. 7.

Fig. 7.

(A) Antitumor effect of SpHL (control group), DOX, SpHL-DOX, and SpHL-DOX-Fol on the growth of 4T1 breast tumor-bearing female BALB/c mice. Each treatment was intravenously administered 4 times, every 3 days, at dose of 5 mg/kg. Data are expressed by the mean ± standard deviation of the mean (n = 7). Growth curves were analyzed by regression. aRepresents statistical differences (P < 0.05) between SpHL and SpHL-DOX-Fol treatments. bRepresents statistical differences (P < 0.05) between DOX and SpHL-DOX treatments. bRepresents statistical differences (P < 0.05) between SpHL-DOX and SpHL-DOX-Fol treatments. (B) RTV analysis of theSpHL (control group), DOX, SpHL-DOX, and SpHL-DOX-Fol treatments. Data are expressed by the mean ± standard deviation of the *1 mean (n = 7). aRepresents statistical differences (P < 0.05) between DOX, SpHL-DOX or SpHL-DOX-Fol, and SpHL treatments. bRepresents statistical differences (P < 0.05) between DOX and SpHL-DOX or SpHL-DOX-Fol treatments. cRepresents statistical differences (P < 0.05) between SpHL-DOX and SpHL-DOX-Fol treatments. (C) Body weight variation percentage between D0 and D12. Data are expressed by the mean ± standard deviation of the mean (n = 7). aRepresents statistical differences (P < 0.05) between DOX, SpHL-DOX or SpHL-DOX-Fol, and SpHL treatments.